Amgen Inc. (LON: 0R0T)

Market Cap	112.61B
Revenue (ttm)	24.27B
Net Income (ttm)	3.16B
Shares Out	n/a
EPS (ttm)	5.84
PE Ratio	35.68
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	Feb 14, 2025

Volume	42,166
Open	269.61
Previous Close	259.00
Day's Range	262.80 - 269.61
52-Week Range	253.20 - 330.26
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 4, 2025

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; N...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1980
• Employees: 26,700
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0R0T

Financial Performance

In 2023, Amgen's revenue was $28.19 billion, an increase of 7.09% compared to the previous year's $26.32 billion. Earnings were $6.72 billion, an increase of 2.52%.

Financial numbers in USD